Skip to content
Clinical Trials – home

NZOZ Neuro- Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy

Verified siteinfoFast reply

Poland Ul. Wierzbowa 2/2, 61-853 Poznan, Poland

  • 10 trials recruiting
  • Myasthenia gravis · Relapsing multiple sclerosis · Dementia Alzheimer's type
  • Adult patients

About Specializations

NZOZ Neuro- Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy in Poznan, Poland specialises in clinical trials of conditions such as Myasthenia gravis, Relapsing multiple sclerosis, Dementia Alzheimer's type, Diabetic neuropathy, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

The site conducts trials aimed at reducing the burden of heart and blood‑vessel conditions, testing new therapies to prevent events such as acute myocardial infarction, stroke, and complications of atrial fibrillation.

  • Prevention strategies for acute myocardial infarction
  • Stroke risk reduction in atrial fibrillation
  • Management of atherosclerotic cardiovascular disease
  • Outcomes in patients with heart failure
  • Comparative effectiveness of novel anticoagulants

NZOZ Neuro‑Kard Ilkowski i Partnerzy supports these studies to improve cardiovascular health and long‑term survival for patients.

Immune System Diseases

Research focuses on autoimmune disorders, evaluating innovative biologics and immune‑modulating agents to improve control of diseases such as myasthenia gravis and multiple sclerosis.

  • New therapies for generalized myasthenia gravis
  • Treatment options for ocular myasthenia gravis
  • Disease‑modifying approaches in relapsing multiple sclerosis
  • Strategies for progressive multiple sclerosis subtypes
  • Safety profiling of emerging autoimmune disease drugs

These trials aim to enhance quality of life by reducing relapse rates and stabilizing immune activity.

Musculoskeletal Diseases

Studies address chronic pain and muscle tone disorders, testing non‑opioid analgesics and injectable therapies to relieve pain and improve function.

  • Non‑opioid options for chronic low back pain
  • Relief of diabetic peripheral neuropathic pain
  • Management of upper‑limb spasticity after stroke or brain injury
  • Safety of botulinum toxin injections for spasticity
  • Pain reduction in distal sensory polyneuropathy

The goal is to provide patients with safer pain relief and better mobility without reliance on opioids.

Nervous System Diseases

A broad program explores neurodegenerative and cognitive disorders, including Alzheimer’s disease, various forms of dementia, and early cognitive impairment, testing disease‑modifying and symptomatic agents.

  • Early Alzheimer’s disease therapies targeting inflammation
  • Cognitive improvement in mild cognitive impairment and early dementia
  • Management of agitation in Alzheimer’s‑type dementia
  • Tau‑targeted treatments for neurodegeneration
  • Assessment tools for neurocognitive disorders

The neurology department at the centre leads these efforts to slow disease progression and support patient independence.

Nutritional and Metabolic Diseases

Trials focus on obesity and metabolic health, evaluating novel agents that influence weight regulation and metabolic pathways to lower cardiovascular risk.

  • Efficacy of new treatments for obesity
  • Impact of semaglutide on cognition in metabolic disease
  • Safety profiling of emerging metabolic disease drugs
  • Dual‑agonist strategies for body‑weight management
  • Outcomes related to metabolic syndrome

These studies aim to provide patients with effective weight‑loss options that also improve overall metabolic health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Site location
Ul. Wierzbowa 2/261-853 PoznanPoland
Recruiting now
10 trials
Conditions studied
23
Partner status
Verified site

More sites in PoznanPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

39 clinical trials

Phase 2 Randomized Study of Povetacicept to Assess Safety and Effectiveness in Adults with Generalized Myasthenia Gravis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Povetacicept
  • Sponsor:Vertex Pharmaceuticals Inc.

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

A study to evaluate the safety and how the body uses ublituximab injections in patients with multiple sclerosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ublituximab
  • Sponsor:Tg Therapeutics Inc.

Study on the Effectiveness of Ublituximab and Drug Combination for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cetirizine
  • Sponsor:Tg Therapeutics Inc.

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

AUR200 for Patients with Generalized Myasthenia Gravis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AUR200
  • Sponsor:Aurinia Pharmaceuticals Inc.

A study of IM-101 in adults with generalized myasthenia gravis or ocular myasthenia gravis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:IM-101
  • Sponsor:Immunabs Inc.

A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effects of Vidofludimus Calcium (IMU-838) in Patients with Progressive Multiple Sclerosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium
  • Sponsor:Immunic AG

Myasthenia gravis

Not yet recruiting

Phase 2 Study to Evaluate Efficacy and Safety of Ublituximab Maintenance after Induction with Efgartigimod Alfa in Adults with Myasthenia Gravis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Tg Therapeutics Inc.

Obesity+1

Not yet recruiting

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.